We are live on ! Find out more
CMTA

Clementia Pharmaceuticals Inc.
CMTA

Delisted

CMTA was delisted on the 17th of April, 2019.

Back to rankings

45 hedge funds and large institutions have $353M invested in Clementia Pharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
45
Holders Change
+45
Holders Change %
–
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
45
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$170M
2
NMC
NEA Management Company
Maryland
+$35M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.6M
4
DCM
Driehaus Capital Management
Illinois
+$13.4M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$12.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$176M +$170M +10,425,225 New
NMC
2
NEA Management Company
Maryland
$36.2M +$35M +2,141,697 New
Wellington Management Group
3
Wellington Management Group
Massachusetts
$14M +$13.6M +831,504 New
DCM
4
Driehaus Capital Management
Illinois
$13.8M +$13.4M +819,508 New
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$12.8M +$12.4M +759,792 New
JP Morgan Chase
6
JP Morgan Chase
New York
$10.9M +$10.7M +653,722 New
RCM
7
RA Capital Management
Massachusetts
$9.89M +$9.57M +585,403 New
Fidelity Investments
8
Fidelity Investments
Massachusetts
$8.45M +$8.17M +500,000 New
DM
9
Deerfield Management
New York
$7.81M +$7.56M +462,387 New
PA
10
Perceptive Advisors
New York
$6.29M +$5.76M +352,250 New
BlackRock
11
BlackRock
New York
$6.01M +$5.82M +356,100 New
RSCM
12
Rock Springs Capital Management
Maryland
$5.83M +$5.64M +345,000 New
WMSA
13
Weiss Multi-Strategy Advisers
New York
$5.78M +$5.59M +342,256 New
PHS
14
PFM Health Sciences
California
$5.7M +$5.51M +337,201 New
BBA
15
Baker Bros. Advisors
New York
$4.22M +$4.09M +250,000 New
ACH
16
ArrowMark Colorado Holdings
Colorado
$3.86M +$3.73M +228,323 New
EC
17
EcoR1 Capital
California
$3.28M +$3.17M +194,166 New
Millennium Management
18
Millennium Management
New York
$3.24M +$3.14M +191,974 New
SFM
19
Sphera Funds Management
Israel
$2.75M +$2.66M +163,000 New
Citadel Advisors
20
Citadel Advisors
Florida
$2.06M +$1.99M +122,040 New
Neuberger Berman Group
21
Neuberger Berman Group
New York
$1.69M +$1.63M +100,000 New
MWNA
22
Marshall Wace North America
New York
$1.61M +$1.55M +94,682 New
Alyeska Investment Group
23
Alyeska Investment Group
Illinois
$1.35M +$1.31M +80,000 New
Morgan Stanley
24
Morgan Stanley
New York
$1.14M +$1.11M +67,618 New
DCM
25
DAFNA Capital Management
California
$1.01M +$981K +60,000 New
1
2

CMTA Hedge Fund Activity: Q3 2017 in Review

45 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q3 2017, worth a combined $353M.

Buyers outnumbered sellers: 45 funds opened new CMTA positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $170M.

  • 45 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q3 2017, up from 0 in Q2 2017.
  • Funds reported $353M of Clementia Pharmaceuticals Inc. stock for Q3 2017.
  • 45 funds opened new Clementia Pharmaceuticals Inc. positions in Q3 2017 and 0 closed out, a net change of +45 holders.
  • The largest Clementia Pharmaceuticals Inc. buyer in Q3 2017 was OrbiMed, an estimated $170M added.

Based on aggregated 13F filings for Q3 2017.